Evidence map›Paper›PMID 42816465›Full record

Trial reportSignal transduction and targeted therapy2026

Safety and efficacy of human gingiva-derived mesenchymal stem cells in patients with type 1 diabetes: a double-blind, randomized, placebo-controlled, phase 1 trial.

Qi Tang, Li Zhou, Liwen Fan, Wei Zhang, Xixiang Tang, Donglan Zeng, Mei Li, Yanhua Zhu, Mengyin Cai, Jia Yuan and 3 more

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qi Tang *Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology & Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Li Zhou *Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology & Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Liwen Fan *Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology & Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Wei Zhang *Department of Clinical Immunology Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xixiang TangVIP Medical Service Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Donglan ZengDepartment of Clinical Immunology Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Mei LiVIP Medical Service Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yanhua ZhuDepartment of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology & Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Mengyin CaiDepartment of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology & Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jia YuanDepartment of Stomatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zheng ChenDepartment of Stomatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Song Guo ZhengDepartment of Immunology, School of Cell & Gene Therapy, Songjiang Institute and Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Song.Zheng@shsmu.edu.cn.ORCID http://orcid.org/0000-0002-5611-4774
Yanming ChenDepartment of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology & Guangzhou Municipal Key Laboratory of Mechanistic and Translational Obesity Research, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. chyanm@mail.sysu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current therapies for type 1 diabetes mellitus (T1DM) rarely halt progressive β-cell function loss due to autoimmune attack. Human gingiva-derived mesenchymal stem cells (GMSCs) have been shown to have therapeutic effects on a variety of autoimmune diseases through their potent immunomodulatory capacity, but clinical evidence for these effects is lacking in patients with T1DM. Here, we performed a double-blind, randomized, placebo-controlled, phase 1 trial to evaluate the safety and efficacy of GMSC therapy in T1DM patients (ChiCTR1800018339). Patients received 4 intravenous injections of GMSCs (1.0 × 10

Indexed as

Diabetes Mellitus, Type 1GingivaMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAdultDouble-Blind MethodFemaleHumansInsulinInsulin-Secreting CellsMaleMiddle AgedInsulin

Identifiers

PMID42816465
PMCPMC13627707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.